Tsc-204-C0702
Oropharynx Squamous Cell Carcinoma
Explore 17 assets in Oropharynx Squamous Cell Carcinoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
TScan Therapeutics, Inc.
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05973487CT.gov A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Oropharynx Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tsc-204-C0702 (this asset) | TScan Therapeutics, Inc. | P1 | CC · 41 |
| Cetuximab | National Cancer Institute (NCI) | P1/2 | B |
| Irinotecan | AIDS Malignancy Consortium | P1/2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| had5-hpv vaccine | ImmunityBio, Inc. | P2 | CCC |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | CCC |
+23 more in the Oropharynx Squamous Cell Carcinoma cohort
Other indications for Tsc-204-C0702
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Verrucous Carcinoma | — | P1 | CC · 43 |
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Anogenital Human Papillomavirus Infection | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tsc-204-C0702 in Oropharynx Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tsc-204-c0702-oropharynx-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →